Summit Therapeutics (SMMT) Research & Development (2022 - 2025)
Summit Therapeutics (SMMT) has disclosed Research & Development for 4 consecutive years, with $147.3 million as the latest value for Q4 2025.
- For the quarter ending Q4 2025, Research & Development rose 186.66% year-over-year to $147.3 million, compared with a TTM value of $537.7 million through Dec 2025, up 256.6%, and an annual FY2025 reading of $537.7 million, up 256.6% over the prior year.
- Research & Development was $147.3 million for Q4 2025 at Summit Therapeutics, up from $131.1 million in the prior quarter.
- Across five years, Research & Development topped out at $208.0 million in Q2 2025 and bottomed at $5.4 million in Q4 2022.
- Average Research & Development over 4 years is $57.9 million, with a median of $30.9 million recorded in 2024.
- Peak annual rise in Research & Development hit 575.44% in 2025, while the deepest fall reached 66.05% in 2025.
- Year by year, Research & Development stood at $5.4 million in 2022, then surged by 360.71% to $24.8 million in 2023, then skyrocketed by 107.07% to $51.4 million in 2024, then skyrocketed by 186.66% to $147.3 million in 2025.
- Business Quant data shows Research & Development for SMMT at $147.3 million in Q4 2025, $131.1 million in Q3 2025, and $208.0 million in Q2 2025.